Kronos Worldwide, Inc. produces and markets titanium dioxide pigments (TiO2) in Europe, North America, the Asia Pacific, and internationally. The company produces TiO2 in two crystalline forms, rutile and anatase to impart whiteness, brightness, opacity, and durability for various products, including paints, coatings, plastics, paper, fibers, and ceramics, as well as for various specialty products, such as inks, foods, and cosmetics and pharmaceuticals. It also produces ilmenite, a raw material used directly as a feedstock by sulfate-process TiO2 plants; iron-based chemicals, which are used as treatment and conditioning agents for industrial effluents and municipal wastewater, as well as in the manufacture of iron pigments, cement, and agricultural products; specialty chemicals for use in the formulation of pearlescent pigments, and production of electroceramic capacitors for cell phones and other electronic devices, as well as for use in natural gas pipe, and other specialty applications. In addition, the company provides technical services for its products. It sells its products under the KRONOS brand through agents and distributors to paint, plastics, decorative laminate, and paper manufacturers. The company was founded in 1916 and is headquartered in Dallas, Texas. Kronos Worldwide, Inc. is a subsidiary of Valhi, Inc.

Kronos Worldwide, Inc.

The latest update is out from Kron Teknoloji AS ( ($TR:KRONT) ). Trading in Kron Teknoloji AS shares on Borsa Istanbul was temporarily shifted from...

Circuit Breaker Triggers Call Auction in Kron Teknoloji Shares

There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Kronos Worldwide (KRO) and Corteva (CTVA) with bullis...

Analysts Offer Insights on Materials Companies: Kronos Worldwide (KRO) and Corteva (CTVA)

Kross Limited ( ($IN:KROSS) ) has shared an update. Kross Limited has announced that its 35th Annual General Meeting will be held on 16 September 2...

Kross Limited Sets 35th AGM as Fully Virtual Meeting in September

In a report released today, from Bank of America Securities reiterated a Hold rating on Keros Therapeutics, with a price target of $17.00. In addit...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KRO	$8.43	-0.24%	241.22K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KRO	$8.43	-0.2%	241.22K
3
4
5
6

KRO

Get Kronos Worldwide, Inc. Data in Excel

Get Kronos Worldwide, Inc. Data in Excel